Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

DESTINY-Breast03: safety follow-up results

DESTINY-Breast03: practice-changing results from ESMO 2021

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A

Highlights from ESMO: DESTINY-Breast03

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer

HER2+ mBC: Study Design and Results of DESTINY-Breast01

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC

Dr. Erika Hamilton Presents Safety Update DESTINY breast03

GS3-01: "Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic..."

DESTINY-Breast04: practice-changing results for HER2-low breast cancer